Podcast & Infographic

Menopause and CVD risk

Lina Badimon, Spain

22 September 2026

Save The Date
scroll-down-icon

Click to Listen to the Podcast

Download the infographic

Overview

The risk of CVD increases with age and often coincides with the onset of menopause in women [Uddenberg, 2024]. The menopause is a significant transition and is accompanied by many changes including cardio metabolism, shift in body composition, increased blood pressure (BP), disruptions in lipoproteins and insulin resistance. Evidence shows that this transition is a significant risk factor for CVD, especially as the earlier the menopause onset, the greater the CVD risk; recent evidence has investigated the links between endometriosis, early menopause and the connection to CVD risk [Younis, 2024]. Menopause is also significantly associated with an increased CVD risk in women who are classified as obese [Freitas, 2025], in women who have had a higher number of pregnancies [Gou, 2024; Theodorou, 2024] and in women at pre- or early-onset menopause with premature ovarian insufficiency, polycystic ovarian syndrome, pre-term delivery and preeclampsia [Theodorou, 2024]. Hormonal changes, body fat distribution, lipid/metabolic changes and structural/functional vascular modifications all play a role in increasing the risk of CVD following menopause.

Learning Objectives

At the end of the activity, learners should be able to:

  • • Be aware of the significant CVD risk associated with the menopause in women
  • • Have knowledge of the risk factors underlying CVD during the menopause
  • • Be familiar with the interactions between CV risk, CVD, menopause and different hormone therapies when making clinical treatment decisions

Target Audience

Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who diagnose and manage patients with CVD and hypertension.

Language

English with simultaneous translation into Russian and Chinese

Back to Main page

Podcast & Infographic
Menopause and CVD risk

Launch 22 September 2026

Faculty

Lina Badimon

Lina Badimon

Medical School, UVic-UCC, IRIS-CC
Cardiovascular Research Foundation for Health and innovation
Barcelona, Spain
Biography

Save the Date

Download

FUNDING

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.

· Lina Badimon ·

Lina Badimon is Professor of Medicine at the Medical School of UVic-UCC and Director of the Cardiovascular Research Foundation for Health and Innovation (FICSI). Her research activities focus on atherosclerosis, cardio-metabolic diseases, and ischemic heart disease. She has published over 737 articles in highly qualified journals that include from guidelines on medical practice to basic science, and clinical and translational research. Her work has been highly cited (citations: >80,000; Hindex: 115)) in the scientific literature. She has written more of 250 book chapters. Previous appointments include Director of the Cardiovascular Area at IR-Sant Pau Barcelona (2018-2025); Director of the Cardiovascular Sciences Institute-ICCC/CSIC in Barcelona (2003-2018); and Head of Department of Molecular Pathology and Therapeutics at CSIC/Hospital de la Santa Creu I Sant Pau, Barcelona (1992-2003). Previously in USA, she was Director of the Cardiology-Research Laboratory and Associate Professor of Medicine at the Mount Sinai School of Medicine, NY (1982-1990); and Lecturer in Medicine at Harvard Medical School/Consultant-to-the-Cardiac Unit, at the Massachusetts General Hospital, Boston (1990-1995). She has been Vice-President of European Society of Cardiology and of the Spanish Society of Cardiology, and President of the European Society for Clinical Investigation and of the Spanish Society of Atherosclerosis.

Join our Newsletter!

Stay in the know with our CME updates

Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.